ADAMTS13, recombinant (Adzynma)

Mechanism of action

Replacement therapy

Diseases for which it is established

• Congenital thrombotic thrombocytopenic purpura

Diseases for which it is used

• Acquired thrombotic thrombocytopenic purpura

History of changes in FDA indication

• 2023-11-09: Approved for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Also known as

• Brand name: Adzynma